# reload+after+2024-01-20 13:43:37.573640
address1§2970 Wilderness Place
address2§Suite 100
city§Boulder
state§CO
zip§80301
country§United States
phone§303 417 0500
fax§866 432 3338
website§https://www.biodesix.com
industry§Diagnostics & Research
sector§Healthcare
longBusinessSummary§Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a blood-based NGS. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.
fullTimeEmployees§245
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Scott  Hutton', 'age': 51, 'title': 'President, CEO & Director', 'yearBorn': 1972, 'fiscalYear': 2022, 'totalPay': 632003, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Robin Harper Cowie', 'age': 43, 'title': 'CFO, Secretary & Treasurer', 'yearBorn': 1980, 'fiscalYear': 2022, 'totalPay': 390869, 'exercisedValue': 0, 'unexercisedValue': 146710}, {'maxAge': 1, 'name': 'Dr. Heinrich  Röder', 'title': 'Founder & CTO', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Christopher  Vazquez', 'title': 'VP, Controller & Chief Accounting Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Mark  DeBlock', 'title': 'Vice President of Sales', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Robbie  Lunt', 'title': 'Senior Director of Marketing', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Gary Anthony Pestano Ph.D.', 'age': 56, 'title': 'Chief Development Officer', 'yearBorn': 1967, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Bobbi  Coffin', 'title': 'Chief Growth Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. James R. Jett M.D.', 'title': 'Co-Chief Medical Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Steven C. Springmeyer', 'title': 'Co-Chief Medical Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§8
boardRisk§5
compensationRisk§10
shareHolderRightsRisk§8
overallRisk§9
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.226
priceToSalesTrailing12Months§4.0484786
currency§USD
dateShortInterest§1702598400
forwardEps§-0.49
exchange§NGM
quoteType§EQUITY
shortName§Biodesix, Inc.
longName§Biodesix, Inc.
firstTradeDateEpochUtc§1603891800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§df9e8662-6fbd-3fb4-9173-ec4974f5206d
gmtOffSetMilliseconds§-18000000
targetHighPrice§5.0
targetLowPrice§3.5
targetMeanPrice§4.25
targetMedianPrice§4.25
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§2
quickRatio§0.785
grossMargins§0.70603997
ebitdaMargins§-1.02424
trailingPegRatio§None
